Free Trial

Scancell (SCLP) Competitors

Scancell logo
GBX 10 +0.50 (+5.26%)
As of 07/3/2025 11:43 AM Eastern

SCLP vs. PRTC, OXB, HZD, FARN, VRP, ARIX, BVXP, CIR, 4BB, and AVCT

Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Circassia Group (CIR), 4basebio (4BB), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

Scancell vs. Its Competitors

Scancell (LON:SCLP) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, PureTech Health had 1 more articles in the media than Scancell. MarketBeat recorded 2 mentions for PureTech Health and 1 mentions for Scancell. PureTech Health's average media sentiment score of 1.47 beat Scancell's score of 0.67 indicating that PureTech Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scancell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PureTech Health
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Scancell has higher earnings, but lower revenue than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ScancellN/AN/A-£6.75M-£0.65-15.33
PureTech Health£521.32K745.59-£91.86M-£24.38-5.31

Scancell has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

46.5% of Scancell shares are owned by institutional investors. Comparatively, 79.9% of PureTech Health shares are owned by institutional investors. 5.0% of Scancell shares are owned by insiders. Comparatively, 15.9% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

PureTech Health has a consensus price target of GBX 455, suggesting a potential upside of 251.62%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Scancell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scancell
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Scancell has a net margin of 0.00% compared to PureTech Health's net margin of -17,620.94%. Scancell's return on equity of 98.74% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
ScancellN/A 98.74% -45.28%
PureTech Health -17,620.94%-21.15%-13.39%

Summary

PureTech Health beats Scancell on 11 of the 15 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SCLP vs. The Competition

MetricScancellBiotechnology IndustryMedical SectorLON Exchange
Market Cap£103.57M£128.01M£5.53B£2.96B
Dividend YieldN/A3.74%5.24%5.02%
P/E Ratio-15.333.4227.50146.59
Price / SalesN/A4,204.64421.02240,167.53
Price / Cash7.8613.1936.8927.97
Price / Book-25.6543.018.045.30
Net Income-£6.75M-£92.79M£3.18B£5.90B
7 Day Performance5.26%2.66%2.82%0.92%
1 Month Performance4.99%2.53%3.70%5.20%
1 Year Performance-1.23%178.37%35.41%80.76%

Scancell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SCLP
Scancell
N/AGBX 10
+5.3%
N/A-4.8%£103.57MN/A-15.3351News Coverage
PRTC
PureTech Health
3.0932 of 5 stars
GBX 128.41
+1.3%
GBX 455
+254.3%
-27.7%£385.72M£521.32K-5.27300News Coverage
Insider Trade
OXB
Oxford Biomedica
2.3475 of 5 stars
GBX 318.50
-0.5%
GBX 380
+19.3%
+4.9%£338.57M£98.31M-2.37891Gap Up
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
FARN
Faron Pharmaceuticals Oy
N/AGBX 220
+2.3%
N/A+129.7%£295.35MN/A-5.8834
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Positive News
Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 2,800
+1.8%
N/A-38.2%£146.62M£13.65M18.1112
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
4BB
4basebio
2.1515 of 5 stars
GBX 967.50
-1.8%
GBX 1,600
+65.4%
-39.5%£123.94M£311K-1,240.38101
AVCT
Avacta Group
N/AGBX 30.16
-1.1%
N/A-45.5%£114.60M£26.29M-3.88120News Coverage

Related Companies and Tools


This page (LON:SCLP) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners